Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07658183 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The goal of this clinical trial is to compare the objective response rates (ORR) of different doses of BL0175 in patients with postmenopausal hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. The main questions it aims to answer are: 1. Which dose level of BL0175 demonstrates the optimal ORR? 2. What is the recommended phase 3 dose (RP3D) based on efficacy and safety data across the tested dose levels?
Trial Details
NCT Number NCT07658183
Lead Sponsor Shanghai Best-Link Bioscience, LLC
Conditions
(from sponsor)		 Breast Cancer (Locally Advanced or Metastatic)
Related terms Breast Neoplasms, Neoplasm Metastasis
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov